NASDAQ:NOVN

Novan (NOVN) Stock Forecast, Price & News

$1.19

+0.04 (+3.48%)

(As of 05/30/2023 ET)

Compare

Today's Range: $1.12
▼
$1.20
50-Day Range: $1.11
▼
$1.40
52-Week Range: $0.79
▼
$3.33

Volume: 123,021 shs
Average Volume: 159,389 shs
Market Capitalization: $33.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.33

Novan MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 936.4% Upside
$12.33 Price Target
Short Interest: Bearish
1.74% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.99) to ($0.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

782nd out of 1,009 stocks

Pharmaceutical Preparations Industry

394th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Novan has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.33, Novan has a forecasted upside of 936.4% from its current price of $1.19.
Amount of Analyst Coverage
Novan has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.74% of the outstanding shares of Novan have been sold short.
Short Interest Ratio / Days to Cover
Novan has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Novan has recently increased by 4.45%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Novan does not currently pay a dividend.
Dividend Growth
Novan does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NOVN.

2.7

News and Social Media Coverage

News Sentiment
Novan has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Novan this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for NOVN on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Novan to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novan insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Novan is held by insiders.
Percentage Held by Institutions
Only 20.68% of the stock of Novan is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Novan are expected to grow in the coming year, from ($0.99) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novan is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novan is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Novan has a P/B Ratio of 6.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novan (NASDAQ:NOVN) Stock

Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment involves the promotion of treatments for medical dermatology conditions products. The Research and Development Operations segment includes the development of nitric oxide-based technology products. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Stock News Headlines

May 21, 2023 | fool.com

Novan (NASDAQ: NOVN)

May 21, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Novan (NASDAQ:NOVN)

May 30, 2023 | Behind the Markets (Ad)

Why Your IRA Could Crash on June 16th

China will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.

May 17, 2023 | americanbankingnews.com

Novan (NASDAQ:NOVN) Posts Earnings Results, Misses Expectations By $0.22 EPS

May 17, 2023 | msn.com

Oppenheimer Maintains Novan (NOVN) Outperform Recommendation

May 16, 2023 | finance.yahoo.com

NOVN: Counting Down to PDUFA

May 15, 2023 | finanznachrichten.de

Novan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023 | markets.businessinsider.com

Novan earnings: here's what Wall Street expects

May 30, 2023 | Behind the Markets (Ad)

Why Your IRA Could Crash on June 16th

China will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.

May 14, 2023 | americanbankingnews.com

Novan (NOVN) to Release Earnings on Monday

May 12, 2023 | msn.com

Earnings Preview: Novan

May 12, 2023 | msn.com

Novan Q1 2023 Earnings Preview

April 20, 2023 | finance.yahoo.com

Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD

April 7, 2023 | americanbankingnews.com

Oppenheimer Research Analysts Reduce Earnings Estimates for Novan, Inc. (NASDAQ:NOVN)

April 5, 2023 | americanbankingnews.com

Q1 2023 Earnings Forecast for Novan, Inc. (NASDAQ:NOVN) Issued By Oppenheimer

April 3, 2023 | msn.com

Novan's Return On Capital Employed Overview

April 3, 2023 | americanbankingnews.com

Novan's (NOVN) "Overweight" Rating Reiterated at Cantor Fitzgerald

April 3, 2023 | americanbankingnews.com

Novan (NASDAQ:NOVN) Raised to Hold at StockNews.com

March 23, 2023 | finance.yahoo.com

Novan to Report Full Year 2022 Financial Results on March 30, 2023

March 21, 2023 | americanbankingnews.com

Analysts Offer Predictions for Novan, Inc.'s Q1 2023 Earnings (NASDAQ:NOVN)

March 7, 2023 | finance.yahoo.com

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024

October 19, 2022 | reuters.com

JPMorgan names Qian as Southeast Asia equity capital markets chief - Reuters

October 14, 2022 | finance.yahoo.com

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® - Yahoo Finance

October 14, 2022 | globenewswire.com

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference - GlobeNewswire

October 14, 2022 | finance.yahoo.com

Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®

October 6, 2022 | finance.yahoo.com

Global Acne Treatment Market (2022 Edition)– Analysis By Treatment, Treatment Modality, End-Users, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028) - Yahoo Finance

October 3, 2022 | finance.yahoo.com

Worldwide Acne Treatment Industry to 2027 - Focus on Retinoids, Antibiotics, Hormonal Drugs, Anti-Inflammatory Drugs and Chemical Peels - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Company Calendar

Last Earnings: 3/30/2023
Today: 5/30/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NOVN
CUSIP: N/A
CIK: 1467154
Web: www.novan.com
Phone: (919) 485-8080
Fax: 919-237-9212
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.33
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +936.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,310,000.00
Net Margins: -128.61%
Pretax Margin: -128.39%
Return on Equity: -700.28%
Return on Assets: -39.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.74
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: $23.68 million
Price / Sales: 1.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.19 per share
Price / Book: 6.26

Miscellaneous

Outstanding Shares: 28,010,000
Free Float: 27,455,000
Market Cap: $33.33 million
Optionable: Not Optionable
Beta: 0.17

Key Executives

Paula Brown Stafford
Chairman, President & Chief Executive Officer

John A. Donofrio
Chief Operating Officer & Executive Vice President

John M. Gay
Secretary, Chief Financial & Accounting Officer

Carri Geer
Chief Technology Officer & Senior Vice President

Tomoko Maeda-Chubachi
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NOVN Stock - Frequently Asked Questions

Should I buy or sell Novan stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NOVN shares.
View NOVN analyst ratings or view top-rated stocks.
What is Novan's stock price forecast for 2023?: 3 brokerages have issued 12-month target prices for Novan's stock. Their NOVN share price forecasts range from $8.00 to $17.00. On average, they predict the company's share price to reach $12.33 in the next year. This suggests a possible upside of 936.4% from the stock's current price.
View analysts price targets for NOVN or view top-rated stocks among Wall Street analysts.
How have NOVN shares performed in 2023?: Novan's stock was trading at $1.46 on January 1st, 2023. Since then, NOVN shares have decreased by 18.5% and is now trading at $1.19.
View the best growth stocks for 2023 here.
When is Novan's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our NOVN earnings forecast.
How were Novan's earnings last quarter?: Novan, Inc. (NASDAQ:NOVN) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.22. The firm earned $10.48 million during the quarter, compared to the consensus estimate of $6.07 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%.
What other stocks do shareholders of Novan own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI).

When did Novan IPO?: (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is Novan's stock symbol?: Novan trades on the NASDAQ under the ticker symbol "NOVN."
Who are Novan's major shareholders?: Novan's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (8.02%), B. Riley Wealth Advisors Inc. (0.67%), Renaissance Technologies LLC (0.30%), Two Sigma Securities LLC (0.14%) and Oak Harbor Wealth Partners LLC (0.10%). Insiders that own company stock include James L Bierman, John M Gay, John W Palmour and Paula B Stafford.
View institutional ownership trends.
How do I buy shares of Novan?: Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novan's stock price today?: One share of NOVN stock can currently be purchased for approximately $1.19.
How much money does Novan make?: Novan (NASDAQ:NOVN) has a market capitalization of $33.33 million and generates $23.68 million in revenue each year. The company earns $-31,310,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.
How can I contact Novan?: Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The official website for the company is www.novan.com. The company can be reached via phone at (919) 485-8080, via email at cikkala@novan.com, or via fax at 919-237-9212.

This page (NASDAQ:NOVN) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial